HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation
In summary, our findings highlight HNRNPC as a prognostic marker in various cancers, including liver cancer, and suggest its involvement in shaping the tumor immune microenvironment. These insights offer potential avenues for improving clinical outcomes in tumors with elevated HNRNPC expression, particularly through immunotherapeutic strategies.
Authors
- Changan Liu (ORCID: https://orcid.org/0000-0003-1704-1004)
- Jianzeng Dong (ORCID: https://orcid.org/0000-0001-7299-7805)
- Zhao Zhang (ORCID: https://orcid.org/0000-0002-2526-1712)
- Yuezhou Zhang (ORCID: https://orcid.org/0000-0001-6420-0536)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2024-11-20
- DOI
- https://doi.org/10.32604/or.2024.055866
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85